Skip to main content

letter

. 1992 Feb 1;304(6822):318. doi: 10.1136/bmj.304.6822.318-b

Appropriate chemotherapy for palliating advanced cancer.

PMCID: PMC1881049 PMID: 1371230

318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

MacLennan I. C., Kelly K., Crockson R. A., Cooper E. H., Cuzick J., Chapman C. Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol. 1988 Apr-Jun;6(2):145–158. doi: 10.1002/hon.2900060215. [DOI] [PubMed] [Google Scholar]
Mandelli F., Tribalto M., Avvisati G., Cantonetti M., Petrucci M. T., Boccadoro M., Pileri A., Marmont F., Resegotti L., Lauta V. Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treat Rev. 1988 Jan;15 (Suppl A):43–48. doi: 10.1016/0305-7372(88)90073-4. [DOI] [PubMed] [Google Scholar]
Rubens R. D., Towlson K. E., Ramirez A. J., Coltart S., Slevin M. L., Terrell C., Timothy A. R. Appropriate chemotherapy for palliating advanced cancer. BMJ. 1992 Jan 4;304(6818):35–40. doi: 10.1136/bmj.304.6818.35. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES